TLR9 agonist and CD40 agonist immunostimulatory combinations

Details TLR9 agonist and CD40 agonist immunostimulatory combinations TLR9 agonist and CD40 agonist immunostimulatory combinations

2011-08-09

2011-08-09

Spector, Lorraine (Department: 1646)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C424S144100, C424S184100, C424S204100, C424S234100, C424S265100, C424S274100, C424S277100, C514S311000, C514S315000, C514S04400A

Reexamination Certificate

active

07993659

ABSTRACT:
The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.

REFERENCES:
R. Fooks, Development of oral vaccines for human use, Curr. Opin. Mol. Therap. 2(10):80-86, 2000.
Krug et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergize with CD40 ligand to induce high amounts of IL-12, Eur. J. Immunol. 31:3026-3037, Oct. 2001.
Singh et al., Recent advances in vaccine adjuvants, Pharm. Res. 19(6):715-728, Jun. 2002.
Vonderheide et al., Phase I study of recombinant human CD40 ligand in cancer patients, J. Clin. Oncol. 19(13):3280-3287, Jul. 1, 2001.
Melief et al., Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes, Immunol. Rev. 188:177-182, Oct. 2002.
Popovic et al., High mobiligy group B1 protein suppresses the human plasmocytoid dendritic cell response to TLR9 agonists, J. Immunol., 177:8701-8707, 2006.
Ito et al., Interferon-alpha and interleukin-12 are indcued differentially by toll-like receptor 7 in human bood dentritic cell subsets, J. Exp. Med. 195(11):1507-1512, Jun. 3, 2002.
Kaisho et al., Toll-like receptors as adjuvant receptors, Biochem. Biophys. Acta, 1589:1-13, 2002.
Vonderheide et al., Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody,, J. Clin. Oncol. 25(7): 876-883, 2007.
Kasran et al., Safety and tolerability of antagonist anti-human CD40 Mab cd5D12 in patientes with moderate to severe Crohn's disease, Alliment pharmacol. Ther. 22:111-122, 2005.
Patel et al., The effect of anti-CD40 ligand in immune thrombocytopenic purpuria, Brit. J. Haematol. 141(4):545-548, 2008.
Advani et al., Phase I study of the humaized anti-CD40 monoclonal antibody dacetumzumab in refractory or recurrent Non-Hodgkin's lymphoma, J. Clin. Oncol. 27(26):4371-4377, 2009.
Ito et al., Specialization, kinetics, and repertoire of type 1 interferon responses by human palsmacytoid predendritic cells, Blood 107(6):2423-2431, Mar. 2006.
Hemmie et al., Small anti-viral compounds activate immune cells via the TLR MyD88-dependent signaling pathway, Nat. Immunol. 3(2):196-200, Feb. 2002.
Cella et al., Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent Th1 polarization, Nat. Immunol. 1(4):305-310, Oct. 2000.
Duramad et al., IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences, Blood, 102(13):4487-4492, Dec. 15, 2003.
O'Hagan D T et al: “Recent developments in adjuvants for vaccines against infectious diseases” Biomolecular Engineering, Elsevier, New York, NY, US, vol. 18, No. 3, Oct. 15, 2001, pp. 69-85.
Ohashi P S et al: “Making and breaking tolerance” Current Opinion in Immunology, Elsevier, Oxford, GB, vol. 14, No. 6, Dec. 1, 2002, pp. 744-759.
Underhill D M et al: “Toll-like receptors: key mediators of microbe detection” Current Opinion in Immunology, Elsevier, Oxford, GB, vol. 14, No. 1, Feb. 1, 2002, pp. 103-110.
EPO Communication with supplementary European search report, Oct. 9, 2008, 2 pages.

Affiliated with

Also associated with

Rating

TLR9 agonist and CD40 agonist immunostimulatory combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with TLR9 agonist and CD40 agonist immunostimulatory combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TLR9 agonist and CD40 agonist immunostimulatory combinations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2708705